X

Trial Profile

Swiss Study of the Impact of Mayzent (Siponimod) on Secondary Progressive Multiple Sclerosis Patients in a Long-term Non-interventional Study

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Siponimod (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms SWISSMASIA
Sponsors Novartis Pharmaceuticals

Most Recent Events

25 Aug 2023 Status changed from recruiting to discontinued due to insufficient patient recruitment.
17 Dec 2021 Status changed from not yet recruiting to recruiting.
22 Oct 2021 Planned initiation date changed from 30 Sep 2021 to 31 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com